GHK-Cu Dosage in Research Protocols: Concentrations, Routes, and Pharmacokinetics

GHK-Cu has been studied at a range of concentrations across different experimental contexts. The following summarizes published research doses, not human use recommendations.

Cell culture models: Collagen stimulation in human dermal fibroblasts was studied at 10^-12 to 10^-9 M (picomolar to nanomolar range), with maximum effect at 10^-9 M.^[1] Keratinocyte and epidermal stem cell models have been studied at 0.1–10 micromolar.^[5] MMP/TIMP modulation in rat dermal fibroblasts was demonstrated at nanomolar concentrations.^[2]

Animal models — systemic: The mouse emphysema study administered GHK-Cu at 0.2, 2, and 20 microg/g/day via intraperitoneal injection on alternate days for 12 weeks.^[12] Aged mouse cognitive studies used systemic administration (dose not specified in available reviews).^[10]

Human clinical trials:

• Hair loss RCT (Lee et al. 2016): topical spray at 50 mg/mL and 100 mg/mL, once daily for 6 months.^[7]
• Skin aging studies (Leyden et al. 2015): topical cream and serum applied twice daily for 8–12 weeks; specific concentration not disclosed but within the 0.02–5% cosmetic formulation range.^[3]
• Skin collagen study (Pickart et al. 2015): topical formulation at unspecified concentration for 12 weeks.^[5]

GHK-Cu is an unmodified tripeptide, and its systemic pharmacokinetics are shaped by this molecular simplicity.

Plasma half-life: Approximately 25–35 min in rodent pharmacokinetic models for intravenous administration. Rapid peptidase degradation and renal filtration account for the short systemic half-life.^[18]

Topical route: Creates a skin depot effect. Local tissue concentrations remain elevated for hours beyond what systemic circulation would sustain, because the peptide is not rapidly cleared from the stratum corneum and dermis once deposited.^[18] This is the pharmacokinetic rationale for topical application despite the short plasma half-life — the target tissue is the site of application.

Subcutaneous route: Produces sustained low-level serum exposure over 6–8 hours; bioavailability estimated at 85–95% in rodent models.^[18] This is the most studied non-topical route for research purposes.

Intraperitoneal route (animal models only): Used in the emphysema and cognitive aging studies; not directly relevant to human administration contexts.^[10][12]

Oral route: Limited bioavailability — estimated 15–25% in rodent models — due to gastric acid degradation and first-pass hepatic metabolism.^[18] The tripeptide is susceptible to digestive proteases; oral delivery requires protective formulation strategies to achieve meaningful systemic exposure.

The published research covers four administration routes, each with distinct pharmacokinetic profiles and evidence quality:

1. Topical (cream, serum, spray, hydrogel, liposome, nanoparticle): The most clinically studied route. Human trial data exists for topical application. Penetration is limited by the peptide's hydrophilicity; advanced delivery systems improve penetration but data remains incomplete for some formulation types.^{[8][18][20][21]}
2. Subcutaneous injection: 85–95% bioavailability in rodent models; serum detection over 6–8 hours.^[18] No published human subcutaneous GHK-Cu trials as of this review.
3. Intraperitoneal (animal models only): Used in the emphysema^[12] and cognitive aging^[10] mouse studies; not a clinically relevant route for human context.
4. Oral: Limited data; bioavailability estimated 15–25% in rodents.^[18] The fragility of unmodified tripeptides in the GI environment makes this route challenging without protective formulation.

Research Context Summary Table